Importantly, the TRC score had no significant prognostic value in a cohort of cytogenetically normal acute myeloid leukemia (AML; n = 162), a cohort of chronic lymphocytic leukemia (Herold CLL cohort, n = 107), and a cohort of diffuse large B-cell lymphoma (Lenz-DLBCL rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] cohort, n = 233; supplemental Figure 1C). The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.